Results 61 to 70 of about 38,007 (143)

Six‐Month Benralizumab Maintenance for Relapsing Chronic Eosinophilic Pneumonia Guided by Eosinophil Kinetics

Respirology Case Reports
Idiopathic chronic eosinophilic pneumonia (ICEP) often relapses upon corticosteroid tapering. Biologics targeting interleukin‐5 (IL‐5) are effective, but optimal dosing intervals remain unclear. We report a case of relapsing ICEP in a patient in her 50s.
Toshiyuki Sumi, Taiki Ishigooka, Kazuya Takeda, Taeka Naraoka, Naoki Shijubou, Yuichi Yamada, Hirofumi Chiba   +6 more
doaj   +1 more source

A real-world study on the safety profile of extended-interval dosing of immune checkpoint inhibitors for melanoma: a single-center analysis in Japan. [PDF]

Front Med (Lausanne), 2023
Ito T, Kaku-Ito Y, Ohno F, Nakahara T.
europepmc   +1 more source

SARS-CoV-2 vaccination strategies: Should the extended dosing interval strategy be implemented in future pandemics?

Travel Medicine and Infectious Disease, 2023
Sandra Valderrama-Beltrán, Juliana Cuervo-Rojas, Samuel Martinez-Vernaza, Carlos A. Alvarez-Moreno, Alfonso J. Rodriguez-Morales   +4 more
doaj   +1 more source

Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors: a real-world retrospective cohort study. [PDF]

ESMO Open, 2023
Colard-Thomas J, Manceron C, Duflos C, Herman F, Simon M, Maria ATJ, Faillie JL, Viala M, Palassin P.   +8 more
europepmc   +1 more source

High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma

Journal for ImmunoTherapy of Cancer
Background Cemiplimab (Libtayo®), a human monoclonal immunoglobulin G4 antibody to the programmed cell death-1 receptor, is approved for the treatment of patients with advanced cutaneous squamous cell carcinoma (CSCC), who are not candidates for curative
Dirk Schadendorf, Thomas K Eigentler, Israel Lowy, Apostolos Papachristos, Samantha Bowyer, Friedegund Meier, Brigitte Dreno, Danny Rischin, Michael R Migden, Annette M Lim, Chrysalyne D Schmults, Brett G M Hughes, Axel Hauschild, Brian Stein, Emmanuel Okoye, Jocelyn Booth, Matthew G Fury, Alexander Guminski, Sophie Dalac, Frank Seebach, Marie Beylot-Barry, Suk-Young Yoo, Nicole Basset-Séguin, Sabiha Trabelsi Messai, Victoria Casado Echarren, Anne J Paccaly, Jenny-Hoa Nguyen   +26 more
doaj   +1 more source

Impact of extended interval dosing of immune checkpoint inhibitors in lung cancer patients during the COVID-19 pandemic. [PDF]

Respir Med Res, 2023
Veron M, Pierret T, Pérol M, Bettega F, Benet J, Denis N, Moro-Sibilot D, Swalduz A, Toffart AC.   +8 more
europepmc   +1 more source

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19. [PDF]

Neurol Neuroimmunol Neuroinflamm, 2021
Rolfes L, Pawlitzki M, Pfeuffer S, Nelke C, Lux A, Pul R, Kleinschnitz C, Kleinschnitz K, Rogall R, Pape K, Bittner S, Zipp F, Warnke C, Goereci Y, Schroeter M, Ingwersen J, Aktas O, Klotz L, Ruck T, Wiendl H, Meuth SG.   +20 more
europepmc   +1 more source

Optimization of hemophilia B treatment via population PK modeling of rIX-FP, including a 3-week regimen

Frontiers in Pediatrics
BackgroundRecombinant factor IX–albumin fusion protein (rIX-FP) enables extended-interval prophylaxis for hemophilia B. While higher trough levels with reduced dosing frequency have been shown vs.
Naoki Terasaka, William Mckeand
doaj   +1 more source

Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations

Clinical Interventions in Aging, 2008
John SunyeczMenopauseRx, Inc., Hopwood, PA, USAAbstract: Postmenopausal osteoporosis is common and underrecognized among elderly women. Osteoporotic fractures cause disability and disfigurement and threaten patients’ mobility, independence, and ...
John Sunyecz
doaj  

Contribution of Trough Concentration Data in the Evaluation of Multiple-Dose Pharmacokinetics for Drugs with Delayed Distributional Equilibrium and Long Half-Life

Drug Design, Development and Therapy, 2020
Suein Choi,1,2 Sangil Jeon,3 Dong-Seok Yim,1,2 Seunghoon Han1,2 1Pharmacometrics Institute for Practical Education and Training (PIPET), College of Medicine, The Catholic University of Korea, Seoul, Korea; 2Department of Pharmacology, College of Medicine,
Choi S, Jeon S, Yim DS, Han S
doaj